About Ensysce
Research Programs
Intellectual Property
Announcements
Related Studies
Contact Us
Recent Announcements
Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up
READ MORE
Ensysce Biosciences Inc. completes Qualifying Financial Transaction matching Emerging Technology Funds from the State of Texas.
READ MORE
Carbon Nanotubes:
Solution for the Therapeutic Delivery of siRNA?
READ MORE
Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA
READ MORE
HomeAbout EnsysceContact Us
 
About Ensysce
Introduction
Ensysce Biosciences, Inc. is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
Carbon nanotubes provide a means to deliver large active agents without modification through natural barriers within the body and specifically into cancer cells. Through its current nationwide research collaborations, Ensysce Biosciences is developing a new class of therapeutics using carbon nanotubes as delivery agents. Proof-of-principal studies have been undertaken with multiple active agents ranging from small interfering RNA (siRNA) to the widely used cancer drugs taxol and doxorubicin.
The goals of the use of carbon nanotubes as delivery agents are to improve efficacy especially of large molecules which have inherent delivery problems, and to reduce side effects of currently used therapies. Both of these goals offer the potential to transform cancer treatment.
Management Team
D. Lynn Kirkpatrick, PhD
President and CEO
Co-founder of ProlX Pharmaceuticals and former Professor of Chemistry and Biochemistry at the University of Regina, Canada, Lynn Kirkpatrick has spent over 25 years in cancer drug discovery and development. From 1999 to 2006 Dr. Kirkpatrick was CEO of ProlX Pharmaceuticals, taking three small molecules from bench to bedside. When ProlX was acquired by Biomira Inc., a publicly traded company she became the Chief Scientific Officer the merged company which changed its name to Oncothyreon, Inc. in 2007. Dr. Kirkpatrick received her PhD from the University of Saskatchewan and did post-doctoral research at Yale University School of Medicine. She has published extensively in the area of targeted cancer drug discovery and development and holds numerous patents for novel cancer drugs.
Russell T. Wong
Chief Legal Counsel
Russell Wong, a principal in the law firm Wong, Cabello, Lutsch, Rutherford & Brucculeri, LLP., focuses on intellectual property and related areas. He was formerly Associate General Counsel and Chief IP Counsel for Compaq Computer Corp. and also was the lead legal counsel for Carbon Nanotechnologies, Inc. from 2000-2007. Russell received his law degree from the University of Houston Law Center.
Bob Gower, PhD
Chairman
Bob Gower was CEO of Lyondell Petrochemical from 1985 through his retirement at the end of 1996. Together with Dr. Richard Smalley, Dr. Gower founded Carbon Nanotechnologies, Inc. (CNI) in 2000 developing fullerene carbon nanotubes for multiple applications. CNI was acquired by Unidym in 2007. Dr. Gower founded Ensysce Biosciences Inc. in early 2008 for the specific focus of using carbon nanotubes in therapeutic areas. Bob received his PhD from the University of Minnesota.
Copyright © 2014 Ensysce Biosciences Inc. All Rights Reserved
Home|About Ensysce|Contact Us
Research Programs|Intellectual Property|Announcements|Related Studies